Cambridge Healthtech Institute 第1回

Advances in Recovery and Purification

( 回収技術と精製技術の進歩 )

下流工程での各種手法の最適化と障害の解消に向けた取り組み

2018年3月21-22日 | Sheraton Lisboa Hotel & Spa | ポルトガル、リスボン

細胞培養でより高い力価が求められるようになるなか、下流工程に携わっているチームは、可能な限り多くの生成物を回収できるようにする一方で、時間を短縮し、障害を低減するよう求められており、既存の手法を最適化しつつ、新たな手法を見つけ出すことが重要な課題となっています。

回収技術と精製技術の進歩をテーマにしたこのカンファレンスプログラムでは、製薬会社や大学の研究者が一堂に会し、生物学的治療薬の収集、回収、精製に対応する技術の最新動向について議論します。会期中は、アフィニティクロマトグラフィー、浄化、深層ろ過、新たなメンブレン、フロキュレーションなどの分野における次世代の技術と戦略に関するデータに重点を置いたケーススタディが発表されるほか、遺伝子治療、抗体薬物複合体、二重特異性抗体、融合タンパク質、抗体フラグメントなどの新たなモダリティに対応する下流工程の戦略も議論されることになっており、出席者が自社の戦略を省みる際の手がかりとなります。

Final Agenda

3月21日 (水)

10:00 Registration and Morning Coffee

10:30 Coffee Break in the Exhibit Hall with Poster Viewing

全体基調セッション

11:15 Chairperson's Remarks

Manuel Carrondo, PhD, Professor of Chemical and Biochemical Engineering, FCT-UNL, Vice President, IBET

11:20 Integrated Drug Substance-Drug Product Development for the Next Generation of Biologics

Hitto Kaufmann, PhD, Global Head, BioPharmaceutics Development & Platform Innovation, Global R&D, Sanofi-Aventis

The rise of next generation biologics brings with it new challenges. This presentation will examine how bioprocessing departments are adapting to evolving and diverse biological pipelines and the role of innovation as a key driver to deliver superior medicines to patients. The convergence of CMC technologies will also be examined using examples from Sanofi where relevant.

11:50 Next-Generation Processes, Technologies and Operations

Eliana Clark, PhD, Vice President, International Manufacturing Operations, Biogen

A critical step in meeting the demand of biologic production worldwide involves implementing disruptive manufacturing technologies, processes and capabilities. This talk will evaluate Biogen's new manufacturing site in Switzerland, due to go online in 2019, including the new processes, operational models and technologies being adopted to drive value through innovation and deliver new medicines in areas such as Alzheimer's.

12:20 Session Break

下流工程の最適化

13:40 Chairperson's Remarks

Nripen Singh, PhD, Manager, Process Development, Bristol Myers Squibb

13:45 Model Based Development of a Conjugation Step

Ernst Broberg Hansen, PhD, Scientific Director, CMC Development, Novo Nordisk A/S

Protein conjugation has become an increasingly important process step in the production of modern pharmaceuticals. This introduces new challenges both regarding cost (e.g. side chain) and further demand for purification. In this presentation we show how chemists and engineers work together and combine chemical reaction with mathematical modelling to obtain a better process understanding and thereby a better process.

14:15 Developing and Improving Manufacturing Process within GMP Environment

Kim_HermansKim Hermans, PhD, MSAT Purification Lead, Sanofi

Increasing productivity and efficiency while maintaining quality and reducing costs are critical success factors for our industry. A case study will be presented on the capacity improvement of an existing downstream GMP manufacturing process.


14:45 Lifecycle Management of a Process Wide Design Space: Case Study

Annika_KleinjensAnnika Kleinjans, PhD, Manager, Development Recovery & DSP, Pharma Technical Development Europe, Roche Diagnostics GmbH

The aim of Continuous Process Verification is to show in real-time that the commercial process is able to deliver material, which meets all critical quality attributes and control strategy requirements. This case study will outline how the extensive process knowledge gained through the establishment of a process-wide design space including definition of critical process parameter

is used to support the goals of CPV. In addition, the talk will highlight how the gained knowledge was applied to develop a new process version.

15:15 Sponsored Presentation (Opportunity Available)

15:45 Refreshment Break in the Exhibit Hall with Poster Viewing

下流工程の最適化

16:25 Optimizing Downstream Processes

Nripen Singh, PhD, Manager, Process Development, Bristol Myers Squibb

16:55 A Microfluidic Platform for Screening and Optimization of Downstream Process of Biopharmaceuticals

Raquel_Aires-BarrosRaquel Aires-Barros, PhD, Professor, Bioengineering, Instituto Superior Tecnico

There is an enhanced demand for more efficient and cost-effective processes. Here, the potential of miniaturization as a high-throughput screening tool to speed up process optimization is explored, considering optimization of antibody extraction conditions with ATPS and chromatographic conditions optimization using a multimodal ligand.


17:25 Modification of Glycosylation of Antibodies during the Upstream or Downstream Stages of a Bioprocess

Michael_ButlerMichael Butler, PhD, CSO, National Institute of Bioprocessing Research & Training (NIBRT)

The glycosylation of any cellular produced protein is often heterogeneous and dependent upon the enzymic activities present in the host cell line as well as the growth conditions during the bioprocess. The glycosylation profile can be controlled during upstream processing by cell engineering or media manipulation during cell growth. An alternative approach is by enzymic remodelling during downstream processing. The relative value of each of these possible strategies will be evaluated for the production of an antibody.

17:55 End of Day

18:00 Dinner Short Course Registration

18:30 Dinner Short Course

18:00 - 21:00 Recommended Dinner Short Course*

SC4: The Challenge of Protein Aggregation and Sub-Visible Particles in Biopharmaceuticals

Attendees will gain a critical overview of the complexity and diversity of the aggregation and sub-visible particles of peptide and protein biopharmaceuticals and on strategies to overcome these issues.

Topics to be covered include: Different aggregation mechanisms; Available techniques for detection of aggregation and impurities (leachables) and how these methods can be applied. Combining analytical methods to ensure detection of aggregates, and new technologies for characterization aggregates will be presented. Aggregation of biopharmaceuticals in human plasma and regulatory aspects will also be addressed.

Instructor:

Tudor Arvinte, PhD, Professor, School of Pharmacy Geneva Lausanne, Switzerland and Chairman, CEO, Therapeomic, Inc.

* Separate registration required.

3月22日 (木)

8:00 Registration and Morning Coffee

次世代の精製技術と治療法

8:25 Chairperson's Remarks

David O'Connell, PhD, Lecturer in Biotherapeutics, School of Biomolecular & Biomedical Science, University College Dublin


KEYNOTE PRESENTATION:

8:30 A Protein A-Derived Domain with Calcium-Dependent Affinity for Use in Antibody Purification

Sophia Hober, PhD, Professor, School of Biotechnology, KTH-Royal Institute of Technology

Protein A affinity chromatography normally gives pure and highly concentrated antibodies. However, when eluting the antibodies from the column, low pH is needed and this can be deleterious for certain antibodies. We have addressed this by developing an engineered protein, ZCa, that has a calcium dependent binding to IgG and thus can be used for antibody purification under mild conditions.

9:00 Affinity Chromatography for the Next Generation of Biotherapeutics: Empirical Approaches to Engineering a Universal Process

David_OConnellDavid O'Connell, PhD, Lecturer in Biotherapeutics, School of Biomolecular & Biomedical Science, University College Dublin

Developing novel affinity methods for the separation of biomolecules requires the integration of biochemical and biophysical parameters that ensure the protein is delivered in an active, native conformation that will greatly depend on how it is captured and how it is released. This talk will focus on engineering protein sequences that facilitate specificity and stability without compromising the integrity of the protein product with some recent examples of successful biotherapeutic candidates.

9:30 Sponsored Presentation (Opportunity Available)

10:00 Scaling-Up of a Downstream Purification Process for a New Recombinant Product (rhFVIII)

Martin_LinhultMartin Linhult, PhD, Head, Head of Bio100 line 1, Octapharma

Octapharma has developed a new process for the production of a recombinant human FVIII product derived from a human cell line (HEK293F cells). Clinical trials are ongoing with positive results. In this presentation I will discuss scale-up of a new downstream purification process and also different affinity ligands that could be applied.


10:30 Coffee Break in the Exhibit Hall with Last Chance for Poster Viewing

新たな治療法に対応する新たな下流工程戦略の最適化

11:15 Development of a Robust Purification Process for a Unique Next-Generation Bispecific Antibody: The κλ Body

Alexandre_CarronAlexandre Carron, PhD, Head, Purification, NovImmune

Novimmune has developed a novel bispecific antibody format, the κλ body. This format does not require any genetic modifications of heavy and light chains and is therefore identical to a fully human monoclonal antibody. The design of a robust and innovative purification process will be presented. The use of novel purification technologies, enabling the elimination of both product and process related contaminants, will be discussed.

11:45 Overcoming Purification Challenges for New Biopharmaceuticals - Cell & Gene Therapy

Cristina_PeixtoCristina Peixto, PhD, Head, Downstream Processing Laboratory, IBET

Novel biopharmaceutical products such as viral vectors and cell-based therapies are a challenging task for downstream processing. This presentation will focus on the recent multicolumn process developed for virus purification, for which chromotographic media selection, predictive models, and process design principles are illustrated.


12:15 Clustering of Biopharmaceuticals in Solutions: A Less Known Physical Phenomenon with Potential Immunogenicity Effects

Tudor_ArvinteTudor Arvinte, PhD, Professor of Biopharmaceutics, Department of Pharmacy, University of Geneva; CEO, Therapeomic, Inc.

Clusters formation in colloidal systems is a less known, however general phenomenon in a biopharmaceutics, from peptides, small proteins, antibodies to viruses. The interactions between the cluster constituents are weak; the clusters are dissociated during standard size analysis like SEC or FFF. Cluster formation is one of the first phenomenon in the onset of aggregation. Cluster properties of different biopharmaceutical will be presented and discussed.

Nanotemper Technologies 12:45 Luncheon Presentation: Improving Protein Validation and Characterization Workflows with Faster Sample Quality Analysis

Speaker to be Announced

13:15 Session Break

新たなパイプラインと治療法

13:45 Chairperson's Remarks

13:50 Antibody Fragments on a Novel Tandem Fab against Celiac Disease - From Inclusion Body to Product Formulation

Olvier_SpadiutOliver Spadiut, PhD, Assistant Professor, Biochemical Engineering, TU Wien

Celiac disease (CD) is one of the most common food-related chronic disorders mediated by storage proteins of different grains. We developed a novel tandem single chain fragment variable (tscFv) acting as a neutralizing agent against prolamins. We introduce this novel tscFv against CD and present our integrated strategy of obtaining active product from E. coli-derived inclusion bodies.

14:20 Real-Time Monitoring of E. coli IB Refolding Processes

Daniel_KronbergerDaniel Kronberger, Head of Downstream Pilot, Process Science, Boehringer Ingelheim RCV GmbH & Co. KG

The performance of IB refolding processes are dependent on several parameters. Scaling up refolding operations can be challenging. For a better control of this unit operation, the actual folding status of the molecule will be monitored online. Eventually, the process step will be quenched at the right time reaching highest yields at lowest possible process time.

14:50 Conferring Protein L Binding Ability to Any Antibody Fragment for Efficient Industrial-Scale Downstream Purification

Philippe_BillialdPhilippe Billiald, PhD, Professor, School of Pharmacy, University Paris Sud

We report a universal method that consists in the design and grafting of a Protein L binding motif to any antibody fragment (Fab, scFv). This strategy doesn't alter the humanness or the antigen-binding properties of the antibody molecule. The process allows efficient industrial-scale downstream purification without requiring fusion to a tag. It can even be considered as an alternative to the current IgG purification gold standard, Protein A.

15:20 Close of Conference


* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。